My research focuses on how gut bacteria metabolize levodopa, the most effective drug for Parkinson’s disease, and how their metabolic products influence disease progression through the gut–brain axis. By combining high-throughput bacterial isolation, LC/MS-based metabolomics, and gnotobiotic mouse models, I aim to clarify how microbial and dietary factors regulate levodopa efficacy and generate bioactive metabolites. These findings will contribute to developing microbiome-based strategies to improve Parkinson’s treatment and deepen our understanding of host–microbe interactions in neurological diseases.